EPCAM and malignant syringoma: BerEP4 has been found to be able to differentiate BCC from other cutaneous pathologies such as squamous cell carcinoma, basosquamous cell carcinoma, collision tumors, sebaceoma, microcystic adnexal carcinoma, ameloblastoma, epidermoid cysts, actinic keratosis, seborrheic keratosis, poroma, lichen planus like keratosis, nevi, hemangioma, inverted follicular keratosis, squamous intraepithelial neoplasia, and sebaceous adenoma/hyperplasia.